Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Sunshine Biopharma (SBFM) over the last 10 years, with Sep 2025 value amounting to $96,163.

  • Sunshine Biopharma's Depreciation & Amortization (CF) rose 48.78% to $96,163 in Q3 2025 from the same period last year, while for Sep 2025 it was $298,888, marking a year-over-year increase of 49.09%. This contributed to the annual value of $223,527 for FY2024, which is 49.87% up from last year.
  • Sunshine Biopharma's Depreciation & Amortization (CF) amounted to $96,163 in Q3 2025, which was up 32.58% from $72,533 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) peaked at $96,163 during Q3 2025, and registered a low of $789 during Q3 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $50,876 (2024), whereas its average is $55,106.
  • As far as peak fluctuations go, Sunshine Biopharma's Depreciation & Amortization (CF) crashed by 75.21% in 2022, and later skyrocketed by 4,614.83% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Depreciation & Amortization (CF) stood at $3,184 in 2021, then surged by 496.01% to $18,977 in 2022, then soared by 123.18% to $42,353 in 2023, then soared by 54.41% to $65,399 in 2024, then skyrocketed by 48.78% to $96,163 in 2025.
  • Its last three reported values are $96,163 in Q3 2025, $72,533 for Q2 2025, and $64,793 during Q1 2025.